Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.81 |
| ▸ | FOXO1 | Q12778 | 13/20 | 0.63 |
| ▸ | FLT3 | P36888 | 2/20 | 0.58 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.56 |
| ▸ | AURKA | O14965 | 1/20 | 0.56 |
| ▸ | KDR | P35968 | 1/20 | 0.56 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22488743 | 0.92 | ACHE (0.84) | ACHEFOXO1FLT3PDE10AAURKA | |
| SCHEMBL25428311 | 0.89 | ACHE (0.79) | ACHEFOXO1FLT3PDE10AAURKA | |
| SCHEMBL30753995 | 0.89 | ACHE (0.79) | ACHEFOXO1FLT3PDE10AAURKA | |
| SCHEMBL29523972 | 0.89 | ACHE (0.75) | ACHEFOXO1FLT3PDE10AAURKA | |
| SCHEMBL25428524 | 0.89 | ACHE (0.75) | ACHEFOXO1FLT3PDE10AAURKA | |
| SCHEMBL26970669 | 0.88 | ACHE (0.65) | ACHEFOXO1PDE10A | |
| SCHEMBL30753996 | 0.88 | ACHE (0.65) | ACHEFOXO1PDE10A | |
| SCHEMBL25426824 | 0.87 | ACHE (0.82) | ACHEFOXO1FLT3PDE10AAURKA | |
| SCHEMBL29523751 | 0.87 | ACHE (0.82) | ACHEFOXO1FLT3PDE10AAURKA | |
| Hydrochloric Acid SCHEMBL25427213 | 0.87 | ACHE (0.78) | ACHEFOXO1FLT3PDE10AAURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220185797-A1 | SELECTIVE FOXO INHIBITORS FOR TREATMENT OF DIABETES AND OTHER DISORDERS RELATED TO IMPAIRED PANCREATIC FUNCTION | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2022-06-16 | — | — | US | disclosed |
| WO-2020198351-A1 | SELECTIVE FOXO INHIBITORS FOR TREATMENT OF DIABETES AND OTHER DISORDERS RELATED TO IMPAIRED PANCREATIC FUNCTION | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2020-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220185797-A1 | SELECTIVE FOXO INHIBITORS FOR TREATMENT OF DIABETES AND OTHER DISORDERS RELATED TO IMPAIRED PANCREATIC FUNCTION | FOXO1, FOXO3, FOXK1 | ACHE 4176/4885FOXO1 1/4885FLT3 3438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.